Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced that the World Intellectual Property Organization (“WIPO”) published its international patent application: PCT/IB2022/052347. Titled “Improved Methods for the Use of Psychedelics,” the PCT application covers the intravenous administration of psilocybin and psilocin and expands and strengthens the IP that Tryp uses to develop its exclusive TRP-8803, an IV formulation of psilocin designed to be administered in conjunction with psychotherapy. According to the announcement, the patent application covers the company’s exclusive formulation and delivery system that has proven to enhance the positive effects of psilocybin and in particular psilocin; the system also significantly reduces the limitations that psilocybin has shown when administered in other ways, such as oral, nasal and sublingual. “The oral administration of psilocybin has yielded valuable progress in the combined use of psychedelics and psychotherapy, but oral therapies also have acknowledged limitations,” said Tryp Therapeutics CEO Jim Gilligan in the press release. “We are excited to introduce the unique and proprietary IV administration of TRP-8803, which we believe can change the landscape for psilocybin-based therapies. . . In addition to providing the clinician with greater control over the psychedelic experience, from initiating the psychedelic experience, to achieving targeted blood levels, to a controlled duration of the experience, TRP-8803 also enables a shorter overall clinical session. Our ability to reduce the in-clinic experience from eight hours to approximately two hours is not only appealing to patients, but we also expect it to create a more scalable model for the broad and efficient roll out of psychedelic treatment, not just for the indications we’re focused on but other indications as well. We remain focused on expanding our patent portfolio as we continue to develop novel, scalable, psychedelic and psychotherapy treatments for broader indications, and with the publication of the PCT we look forward to discussing the merits of TRP-8803 with collaborators and investors.”
To view the full release, visit https://ibn.fm/liipM
About Tryp Therapeutics Inc.
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric-Disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain and other indications. The company has begun enrolling patients in its phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.